Hydrocodone controlled release(DURECT Corp)

FRIDAY, Jan. 31, 2025 -- Distribution of prescribed opioid analgesics is lower in majority non-White versus majority White communities across all levels of socioeconomic deprivation, according to a study published online Jan. 21 in PAIN . Ju-Chen Hu, Ph.D., from Weill Cornell Medicine in New York City, and colleagues examined quarterly per-capita distribution of oxycodone, hydrocodone, and morphine (in oral morphine milligram equivalents [MMEs]) by communities' racial/ethnic and socioeconomic profiles using 2011 to 2021 national data. Communities were classified as majority White versus majority non-White. The researchers found that across all levels of socioeconomic deprivation, majority non-White communities had at least 40 percent lower mean adjusted per-capita distribution than majority White communities. The adjusted mean per-capita distribution was 46.0 versus 82.8 MMEs for majority non-White versus majority White communities among the least deprived communities. The corresponding distribution was 78.0 versus 134.4 MMEs among the most deprived communities. The lower distribution in majority non-White communities was significant across all levels of socioeconomic deprivation and all study years. Compared with majority White communities, in majority non-White communities, the availability of commonly prescribed opioid analgesics was substantially lower across all levels of socioeconomic deprivation. "Our findings highlight the need for careful consideration and adjustments to current policies to mitigate adverse consequences of further restricted access to effective pain management for patients in racially and ethnically minoritized communities for whom opioid therapies are appropriate," the authors write. One author disclosed ties to the publishing and health technology industries; a second author disclosed ties to the pharmaceutical industry.

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative intended to avoid the addiction risks posed by opioid medications. The regulatory decision announced late Thursday covers the treatment of moderate-to-severe acute pain in adults. Acute pain is defined as pain that lasts less than three months, such as aches following an injury or a surgical procedure. The Boston-based company’s new drug, a twice-daily pill known in development as suzetrigine, will be marketed under the brand name Journavx. “Today’s approval is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research, said in the agency’s approval announcement. “A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment option.” Exclusive Improving the Healthcare Financial Experience to Help Care Flow Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all. By Stephanie Baum The addiction risks of opioids come from their targeting of receptors in the central nervous system. But before pain signals reach the brain, they travel across pathways in the peripheral nervous system. Journavx targets one of these pathways, a sodium channel called NaV1.8. The drug is a small molecule designed to selectively block this channel without hitting other related sodium channels, which could lead to adverse effects. The drug comes from a pain research program that began at Vertex about 25 years ago. FDA approval of Journavx is based on the results of two Phase 3 studies, one that tested the drug after abdominoplasty (tummy tuck) surgery and the other after bunionectomy surgery. Both studies met the main goal of showing statistically significant improvement compared to placebo according to a pain rating scale. The studies also included as a comparator the drug Vicodin, an inexpensive painkiller that pairs the opioid hydrocodone with the main pharmaceutical ingredient in Tylenol. On this secondary trial measure, the results were disappointing. In tummy tuck patients, the numerical improvement achieved by suzetrigine fell short of statistical significance compared to Vicodin. In bunion surgery patients, Vicodin beat suzetrigine. The Vertex drug was safe and well tolerated in these studies. Vertex reported no addiction problems in the studies. Vertex is also developing Journavx for chronic pain, but there have been mixed results so far. In a Phase 2 test in painful lumbosacral radiculopathy (lower back pain), data released last month showed that despite meeting the main goal according to a pain rating scale, the placebo arm posted a similar response. The study was not powered or designed to show differentiation from placebo, but Vertex’s stock price still took a hit. The company said it plans to advance the drug to a pivotal test in this indication, pending discussions with regulators. A Phase 3 test in painful diabetic peripheral neuropathy is ongoing. In a note sent to investors after the back pain trial readout, William Blair analyst Myles Minter said the lack of separation from placebo in that trial increases the risk for the ongoing Phase 3 diabetic peripheral neuropathy test. presented by Artificial Intelligence What Keeps Healthcare CIOs Up at Night: Balancing Technology Investments with Consumer Expectations When it comes to managing inbound phone calls, underperformance has devastating cost implications. By Stephanie Baum Vertex set a $15.50 per pill price for Journavx. That’s slightly higher than the $12 per pill price that Leerink Partners modeled. A December report by the Institute for Clinical and Economic Review concluded that compared to treatment with Vicodin, the Vertex drug would lead to savings that mainly come from avoiding the excess healthcare costs associated with opioid use disorder. A recent regulatory change should support reimbursement of the new Vertex product. The Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act took effect on Jan. 1, requiring Medicare to provide separate reimbursement for qualifying non-opioid pain drugs. A goal of the legislation is to increase access to alternative pain drugs to reduce opioid use. Leerink analyst David Risinger wrote in a research note that the Journavx label represents the best-case scenario for Vertex. There is no language for addiction or abuse potential, which Leerink expects will be critical to the drug’s utilization. The firm sees Journavx as the first in a series of novel non-opioid pain medicines coming from Vertex. Risinger said Leerink projects Journavx and follow-on NaV1.8 inhibitors for acute and neuropathic pain could top $10 billion in peak sales. That’s important for Vertex, which is working to diversify its portfolio beyond the cystic fibrosis products that currently bring in the vast majority of its revenue. Photo by Vertex Pharmaceuticals